We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.17B
1-Year Est. Return
92.19%
This Fund
S&P 500
This Quarter
Est. Return
-5.07%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$3.24B
AUM Growth
-$48.8M
(-1.5%)
Cap. Flow
-$269M
Cap. Flow
% of AUM
-8.31%
Top 10 Holdings %
Top 10 Hldgs %
35.11%
Holding
101
New
30
Increased
21
Reduced
24
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$134M |
| 2 |
HCA Healthcare
HCA
|
+$114M |
| 3 |
Apple
AAPL
|
+$108M |
| 4 |
Elevance Health
ELV
|
+$69.3M |
| 5 |
Gilead Sciences
GILD
|
+$69.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AerCap
AER
|
+$126M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$122M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$91.5M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$85.3M |
| 5 |
Textron
TXT
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.14% |
| 2 | Miscellaneous | 15.69% |
| 3 | Technology | 13.88% |
| 4 | Financials | 7.38% |
| 5 | Communication Services | 6.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
HCA Healthcare
HCA
$87.7B
| $159M | 4.91% |
2,038,188
+1,636,371
| +407% | +$114M |
|
|
2
AbbVie
ABBV
$453B
| $137M | 4.22% |
+2,396,328
| New | +$134M |
|
|
3
Apple
AAPL
$4.67T
| $118M | 3.65% |
+4,339,012
| New | +$108M |
|
4
Bristol-Myers Squibb
BMY
$136B
| $118M | 3.65% |
1,850,371
-1,003,469
| -35% | -$63.3M |
|
|
5
CALL
Bristol-Myers Squibb
BMY
$136B
| $117M | 3.6% |
1,828,000
+950,900
| +108% | +$60M |
|
6
CALL
iShares S&P 100 ETF
OEF
$20.5B
| $111M | 3.42% |
+424,700
| New | +$37M |
|
|
WBA
7
DELISTED
Walgreens Boots Alliance
WBA
| $101M | 3.12% |
1,199,318
-1,067,878
| -47% | -$85.3M |
|
8
Jazz Pharmaceuticals
JAZZ
$16B
| $99.8M | 3.08% |
764,384
+252,534
| +49% | +$31.4M |
|
9
Lam Research
LRCX
$385B
| $90.7M | 2.8% |
10,986,460
+2,938,130
| +37% | +$21.4M |
|
|
ALDR
10
DELISTED
Alder Biopharmaceuticals
ALDR
| $86.8M | 2.68% |
3,542,647
+1,652,617
| +87% | +$38.3M |
|
11
Edwards Lifesciences
EW
$51.8B
| $85.5M | 2.64% |
2,907,021
-615,273
| -17% | -$17M |
|
|
AGN
12
DELISTED
Allergan plc
AGN
| $84.2M | 2.6% |
314,106
-178,353
| -36% | -$51.1M |
|
13
Palo Alto Networks
PANW
$272B
| $81.1M | 2.5% |
2,983,572
-1,929,540
| -39% | -$47.4M |
|
14
Alphabet (Google) Class A
GOOGL
$4.14T
| $77.9M | 2.4% |
2,042,300
-708,420
| -26% | -$26.1M |
|
|
15
Gilead Sciences
GILD
$187B
| $76.7M | 2.37% |
835,032
+768,845
| +1,162% | +$69.3M |
|
16
Amazon
AMZN
$2.79T
| $75.8M | 2.34% |
2,553,280
-387,920
| -13% | -$11M |
|
17
Microsoft
MSFT
$3.71T
| $75.5M | 2.33% |
1,367,103
+874,960
| +178% | +$45.9M |
|
|
18
Elevance Health
ELV
$88.4B
| $72.1M | 2.22% |
+518,909
| New | +$69.3M |
|
|
MDCO
19
DELISTED
Medicines Co
MDCO
| $70.7M | 2.18% |
2,226,207
+159,660
| +8% | +$5.21M |
|
20
Universal Health Services
UHS
$10B
| $67.5M | 2.08% |
541,456
-32,449
| -6% | -$3.65M |
|
21
Blackrock
BLK
$174B
| $64.4M | 1.99% |
189,158
+59,958
| +46% | +$19M |
|
22
Heron Therapeutics
HRTX
$65.3M
| $58.4M | 1.8% |
3,073,470
+296,006
| +11% | +$5.84M |
|
23
PayPal
PYPL
$47B
| $57.4M | 1.77% |
+1,487,245
| New | +$53.7M |
|
|
24
CALL
AbbVie
ABBV
$453B
| $53.2M | 1.64% |
+930,600
| New | +$51.9M |
|
25
Vulcan Materials
VMC
$34B
| $52.1M | 1.61% |
493,071
-530,214
| -52% | -$50.2M |
|
Similar funds
JC
PRS
MK
HCP
EC
M
CCM
VFP
PFM Health Sciences's Q1 2016 Portfolio in Review
As of Q1 2016, PFM Health Sciences held 101 positions worth $3.24B, down 1.5% from $3.29B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
PFM Health Sciences withdrew a net $269M in Q1 2016, closing 20 positions and reducing 24 holdings. Its most notable exit was AerCap, an estimated $126M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 54% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, PFM Health Sciences opened a new position in AbbVie worth $137M.
- PFM Health Sciences's largest Q1 2016 buy was AbbVie: 2,396,328 shares worth $137M.
- PFM Health Sciences added most to HCA Healthcare in Q1 2016, an estimated $114M increase.
- PFM Health Sciences's biggest Q1 2016 reduction was Walgreens Boots Alliance, cutting an estimated $85.3M.
- PFM Health Sciences fully exited AerCap in Q1 2016, selling an estimated $126M.
- PFM Health Sciences's ten largest holdings make up 35% of its $3.24B portfolio in Q1 2016.
- PFM Health Sciences opened 30 new positions and closed 20 in Q1 2016.
- PFM Health Sciences's portfolio value fell 1.5% quarter-over-quarter to $3.24B.
Based on PFM Health Sciences's 13F filing for Q1 2016, filed 16 May 2016.